Tema Oncology ETF Rating $37.48 0.00 (0.00%) As of 06/12/2026 03:59 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.71Holdings in CANC have an aggregate rating of Moderate Buy based on 404 analyst ratings issued in the past year covering 23 companies (70.1% of the portfolio).CANC Aggregate Price Target$37.48High Prediction$37.48Average Prediction$37.48Low Prediction$37.48Holdings in CANC have an aggregate price target of $37.48 and a range of $37.48 to $37.48 covering 23 companies (70.1% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy17 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 CANC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.07%RVMDRevolution Medicines$153.871.7998 of 5 stars3.00$123.72 -19.6%22Positive NewsGap Down5.44%LLYEli Lilly and Company$1,137.01+0.4%4.1028 of 5 stars2.87$1,227.74 8.0%30Trending NewsAnalyst RevisionGap Up4.74%LEGNLegend Biotech$35.874.2378 of 5 stars2.67$60.23 67.9%154.22%RHHBYRoche$51.652.3797 of 5 stars2.45$51.50 -0.3%11Analyst Revision4.20%COGTCogent Biosciences$33.102.4836 of 5 stars2.86$43.73 32.1%143.71%MRKMerck & Co., Inc.$119.05+0.0%4.468 of 5 stars2.68$128.18 7.7%19Trending NewsOptions VolumeGap Up3.56%BMYBristol Myers Squibb$57.05-0.1%4.7181 of 5 stars2.37$61.31 7.5%19Trending News3.36%IMNMImmunome$18.383.6804 of 5 stars2.85$33.17 80.4%13Analyst Forecast3.35%NUVLNuvalent$123.251.811 of 5 stars2.20$131.15 6.4%20Trending News3.13%JNJJohnson & Johnson$240.57-0.1%4.417 of 5 stars2.74$253.04 5.2%27Trending NewsInsider Trade3.01%EXELExelixis$53.133.08 of 5 stars2.39$47.35 -10.9%23Positive News2.96%ABBVAbbVie$227.54-0.1%4.4846 of 5 stars2.88$253.43 11.4%25Trending News2.87%BBIOBridgeBio Pharma$66.803.6889 of 5 stars2.85$89.59 34.1%26Positive News2.77%AMGNAmgen$355.203.8153 of 5 stars2.48$354.12 -0.3%31Trending NewsAnalyst Forecast2.33%GMABGenmab A/S$25.084.4342 of 5 stars2.75$37.93 51.2%122.30%CGONCG Oncology$59.562.8091 of 5 stars2.71$81.73 37.2%14Gap Down2.27%IDYAIDEAYA Biosciences$28.982.8026 of 5 stars2.82$50.69 74.9%17Analyst Forecast2.12%CELCCelcuity$88.553.2498 of 5 stars2.83$152.09 71.8%12Positive News1.78%ZLABZai Lab$17.072.7252 of 5 stars2.63$45.83 168.5%81.74%ONCBeOne Medicines$264.484.1229 of 5 stars2.93$390.00 47.5%151.42%ELVNEnliven Therapeutics$46.132.8158 of 5 stars2.86$61.50 33.3%7Trending NewsGap DownHigh Trading Volume1.41%ZYMEZymeworks$22.882.1716 of 5 stars2.82$36.67 60.3%11News Coverage1.34%HALOHalozyme Therapeutics$69.504.2704 of 5 stars2.54$81.60 17.4%13Positive NewsGap Up This page (NASDAQ:CANC) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
